8797 related articles for article (PubMed ID: 33629336)
41. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
42. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
Front Immunol; 2022; 13():919408. PubMed ID: 35935993
[TBL] [Abstract][Full Text] [Related]
45. [Current state of vaccination against SARS-CoV-2].
Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
[TBL] [Abstract][Full Text] [Related]
46. Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists.
Patel N; Bouchard J; Oliver MB; Badowski ME; Carreno JJ;
Pharmacotherapy; 2021 Oct; 41(10):837-850. PubMed ID: 34689348
[TBL] [Abstract][Full Text] [Related]
47. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
Front Public Health; 2022; 10():975781. PubMed ID: 36238255
[TBL] [Abstract][Full Text] [Related]
48. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
49. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
50. Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland.
Paczkowska A; Hoffmann K; Michalak M; Hans-Wytrychowska A; Bryl W; Kopciuch D; Zaprutko T; Ratajczak P; Nowakowska E; Kus K
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335066
[TBL] [Abstract][Full Text] [Related]
51. Frequency and Characteristics of Nodal and Deltoid FDG and
Schroeder DG; Jang S; Johnson DR; Takahashi H; Navin PJ; Broski SM; Thorpe MP; Johnson GB; Young JR
AJR Am J Roentgenol; 2021 Nov; 217(5):1206-1216. PubMed ID: 34009000
[No Abstract] [Full Text] [Related]
52. Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.
Alkhalifah JM; Al Seraihi A; Al-Tawfiq JA; Alshehri BF; Alhaluli AH; Alsulais NM; Alessa MM; Seddiq W; Aljeri T; Qahtani MH; Barry M; Al-Otaiby M
Front Public Health; 2023; 11():1043696. PubMed ID: 36908451
[TBL] [Abstract][Full Text] [Related]
53. COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram.
Raj S; Ogola G; Han J
Acad Radiol; 2022 Apr; 29(4):501-507. PubMed ID: 34906409
[TBL] [Abstract][Full Text] [Related]
54. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
[TBL] [Abstract][Full Text] [Related]
55. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks.
Esmaeilzadeh A; Maleki AJ; Moradi A; Siahmansouri A; Yavari MJ; Karami P; Elahi R
Expert Rev Vaccines; 2022 Oct; 21(10):1377-1394. PubMed ID: 35986451
[TBL] [Abstract][Full Text] [Related]
56. Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience.
Sauserienė J; Liseckienė I; Neverauskė V; Šepetauskienė E; Serapinas D; Mačinskas Š; Šitkauskienė B; Bajoriūnienė I; Vaičiūnienė R; Valius L
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334616
[No Abstract] [Full Text] [Related]
57. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.
Hause AM; Gee J; Baggs J; Abara WE; Marquez P; Thompson D; Su JR; Licata C; Rosenblum HG; Myers TR; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1053-1058. PubMed ID: 34351881
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].
Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F
Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208
[TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
Butt AA; Omer SB; Yan P; Shaikh OS; Mayr FB
Ann Intern Med; 2021 Oct; 174(10):1404-1408. PubMed ID: 34280332
[TBL] [Abstract][Full Text] [Related]
60. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
